January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive decline, according to a new study presented at the annual meeting of the...
Contrast Media
Contrast media, also called contrast agents, are used to enhance the blood and perfusion in tissues. This includes iodine based contrast for on computed tomography (CT), gadolinium based agents for MRI and lipid bubble contrast agents used in ultrasound.
-
-
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pittsburgh Medical Center, discusses the heightened concerns about gadolinium, which may cause adverse effects in some patients.
-
The U.S. Food and Drug Administration (FDA) announced in a new drug safety communication is this week that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) used for magnetic resonance imaging (MRI).
-
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MRI contrast safety issues at RSNA 2017. Read the article “FDA: No Harm in MRI...
-
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly last week to recommend new labels on gadolinium-based contrast agents (GBCAs) warning of the possibility of gadolinium retention in the body following administration. The labels...
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is...
TriHealth in Cincinnati.
Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs)...
News | Contrast Media | February 07, 2018
February 7, 2018 — The American College of Radiology (ACR) introduced a new...
News | Contrast Media | January 30, 2018
January 30, 2018 — Bracco Diagnostics Inc. announced the labeling of its...
News | Contrast Media | January 19, 2018
January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop...
Blog | RSNA 2017 | January 18, 2018 | Dave Fornell
The Radiological Association of North America's (RSNA) 2017 conference will be remembered as the year artificial...
MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).
News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive...
News | Cardiac Imaging | January 09, 2018
January 9, 2018 – Competitive male triathletes face a higher risk of a potentially harmful heart condition called...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of...
The FDA issued new warnings on MRI gadolinium contrast agents.
Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S. Food and Drug Administration (FDA) announced in a new drug safety communication is this week that it is...
Gadolinium-based contrast agents (GBCAs) used in MRI causes gadolinium retention in the brain, skin and bone. However, there have not been any large-scale studies to determine if this presents long-term patient safety issues.
Blog | Magnetic Resonance Imaging (MRI) | December 15, 2017 | Dave Fornell
Over the past couple years covering the news about gadolinium-based contrast agent (GBCA) retention in the brain,...
Technology | Contrast Media | December 12, 2017
December 12, 2017 — Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance...
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring...
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed...
News | Contrast Media | October 10, 2017
October 10, 2017 — Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de...
Image courtesy of Bayer
Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based...
News | Contrast Media | September 12, 2017
September 12, 2017 — The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC)...
